Question 1

What is Huntington disease-like 3?

Accepted Answer

Huntington disease-like 3 is a rare neurodegenerative condition that usually starts in childhood. People with this condition experience a progressive decline in neurological function. The disease is considered similar to Huntington disease but has its own distinct features.

This condition is marked by a mix of movement problems and neurological symptoms. People may show signs of both pyramidal and extrapyramidal abnormalities, which affect motor control, and there can be changes seen on brain imaging, including progressive loss of brain tissue in the frontal cortex and caudate regions.

Question 2

What are the symptoms of Huntington disease-like 3?

Accepted Answer

The symptoms of Huntington disease-like 3 include a variety of movement problems. These include involuntary movements such as chorea, dystonia, and ataxia. There may also be gait instability, spasticity, and seizures. In some cases, mutism can occur. Such symptoms reflect a decline in neurological function over time.

Question 3

What causes Huntington disease-like 3?

Accepted Answer

Huntington disease-like 3 has a genetic basis. Mutations in the HDL3 gene have been associated with the condition, and it is described as autosomal recessive. This means that the condition can be inherited when both copies of the gene in each cell have changes.

Question 4

How is Huntington disease-like 3 inherited?

Accepted Answer

Huntington disease-like 3 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is Huntington disease-like 3?

Accepted Answer

Huntington disease-like 3 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is Huntington disease-like 3 diagnosed?

Accepted Answer

Diagnosis of Huntington disease-like 3 generally involves a careful clinical evaluation including a review of medical history and symptoms. Brain imaging, such as MRI, may show characteristic signs like frontal cortical atrophy and bilateral caudate atrophy. Genetic testing can help confirm changes in the HDL3 gene.

Question 7

Are there treatments for Huntington disease-like 3?

Accepted Answer

Information about treatment is currently limited for this condition.

Question 8

What are the specific movement problems associated with Huntington disease-like 3?

Accepted Answer

Huntington disease-like 3 causes a variety of movement problems. These include involuntary movements like chorea, which are sudden and jerky, as well as dystonia, which causes muscle contractions. People may also experience ataxia, gait instability, spasticity, and in some cases, seizures. These symptoms show how the disease affects motor control over time.

Question 9

How does Huntington disease-like 3 affect daily life and management?

Accepted Answer

Living with Huntington disease-like 3 can be challenging due to the progressive decline in neurological function. Daily activities may become harder because of movement problems and instability. Families may need to adjust routines and seek support for mobility and safety. It's important to work with healthcare providers to find ways to manage symptoms effectively.

Question 10

What is the prognosis for someone with Huntington disease-like 3?

Accepted Answer

Currently, information about the prognosis for Huntington disease-like 3 is limited. Since it is a progressive condition, individuals may experience a decline in their neurological function over time. However, specific details about life expectancy or long-term outcomes are not well established. Ongoing medical support is important for managing the condition.

Question 11

Are there any specialists recommended for managing Huntington disease-like 3?

Accepted Answer

For managing Huntington disease-like 3, it is helpful to work with a team of specialists. Neurologists are key in diagnosing and monitoring the disease. Additionally, physical therapists can assist with movement issues, while occupational therapists can help with daily living skills. Coordinating care with these professionals can improve quality of life.

Organ System	Phenotype Count	Example Features
Brain and nerves	10	Mutism, Dystonia, Abnormal speech pattern
Muscles

Research Type	Count	% of Total
Laboratory research	13	52%

Kisho

Huntington disease-like 3

Overview

Clinical Presentation

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

Latest News & Developments

Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review

UniQure gets an FDA decision date; Teva scraps brain drug study

UniQure snags May Day decision date for Huntington’s gene therapy after arduous year

AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

UniQure tumbles with latest data for Huntington’s gene therapy

Huntington disease-like 3

Overview

Clinical Presentation

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is Huntington disease-like 3?

What are the symptoms of Huntington disease-like 3?

What causes Huntington disease-like 3?

How is Huntington disease-like 3 inherited?

How rare is Huntington disease-like 3?

How is Huntington disease-like 3 diagnosed?

Are there treatments for Huntington disease-like 3?

What are the specific movement problems associated with Huntington disease-like 3?

How does Huntington disease-like 3 affect daily life and management?

What is the prognosis for someone with Huntington disease-like 3?

Are there any specialists recommended for managing Huntington disease-like 3?

Explore clinical features

Recent Publications

Latest News & Developments

Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review

UniQure gets an FDA decision date; Teva scraps brain drug study

UniQure snags May Day decision date for Huntington’s gene therapy after arduous year

AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

UniQure tumbles with latest data for Huntington’s gene therapy